Center for Clinical and Epidemiological Research, Beijing An Zhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing Municipal Key Laboratory of Clinical Epidemiology.
J Atheroscler Thromb. 2023 Nov 1;30(11):1644-1660. doi: 10.5551/jat.63937. Epub 2023 Apr 13.
Experimental studies report that intermediate-density lipoprotein (IDL), the precursor of low-density lipoprotein, promotes atherosclerotic plaque formation. However, whether IDL is involved in the development of atherosclerosis in humans is still unclear. The aim of this community-based study is to examine the association between IDL particle (IDL-P) concentrations and the 5-year progression of carotid atherosclerosis.
Baseline IDL-P concentrations were measured using nuclear magnetic resonance spectroscopy in 927 participants aged 45-74 years with no history of cardiovascular disease (CVD) at baseline. To estimate the association between baseline IDL-P concentrations and 5-year progression of carotid atherosclerosis, indicated by atherosclerotic plaque progression and changes in total plaque area (TPA), multivariable-adjusted regression was employed.
During the 5-year follow-up period, 45.8% of participants developed new plaques. Baseline IDL-P concentrations were significantly associated with the progression of carotid atherosclerosis. Participants in the highest quartile of IDL-P concentrations exhibited 1.36-fold (95% confidence interval [CI]: 1.09-1.68) increased progression of carotid plaque and 1.67-fold (95% CI: 1.04-2.69) higher TPA than those in the lowest quartile. These relationships were independent of baseline concentrations of low-density lipoprotein particles and very-low-density lipoprotein particles and their subclasses.
Elevated IDL-P concentrations were independently associated with the progression of carotid atherosclerosis, suggesting that IDL-P is a novel risk factor for the development of atherosclerosis.
实验研究报告称,中间密度脂蛋白(IDL)是低密度脂蛋白的前体,可促进动脉粥样硬化斑块的形成。然而,IDL 是否参与人类动脉粥样硬化的发展仍不清楚。本社区研究旨在探讨 IDL 颗粒(IDL-P)浓度与颈动脉粥样硬化 5 年进展之间的关系。
在无心血管疾病(CVD)病史的 927 名 45-74 岁的参与者中,使用核磁共振光谱法测量基线 IDL-P 浓度。为了评估基线 IDL-P 浓度与颈动脉粥样硬化 5 年进展(通过动脉粥样硬化斑块进展和总斑块面积[TPA]的变化来表示)之间的关系,采用多变量调整回归。
在 5 年的随访期间,45.8%的参与者出现了新斑块。基线 IDL-P 浓度与颈动脉粥样硬化的进展显著相关。IDL-P 浓度最高四分位组的参与者颈动脉斑块进展的风险增加了 1.36 倍(95%置信区间[CI]:1.09-1.68),TPA 增加了 1.67 倍(95%CI:1.04-2.69),而最低四分位组则相反。这些关系独立于低密度脂蛋白颗粒和极低密度脂蛋白颗粒及其亚类的基线浓度。
升高的 IDL-P 浓度与颈动脉粥样硬化的进展独立相关,表明 IDL-P 是动脉粥样硬化发展的一个新的危险因素。